Iovance Biotherapeutics (IOVA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Key Insights
Critical company metrics and information
Share Price
$9.03Market Cap
$2.75 BillionTotal Outstanding Shares
304.78 Million SharesTotal Employees
557Dividend
No dividendIPO Date
October 15, 2010SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.iovance.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $41.95 Million |
| Net Cash Flow, Continuing | $-65.82 Million |
| Net Cash Flow From Operating Activities | $-58.97 Million |
| Net Cash Flow From Investing Activities, Continuing | $-48.80 Million |
| Exchange Gains/Losses | $1.25 Million |
| Net Cash Flow | $-64.57 Million |
| Net Cash Flow From Financing Activities, Continuing | $41.95 Million |
| Net Cash Flow From Operating Activities, Continuing | $-58.97 Million |
| Net Cash Flow From Investing Activities | $-48.80 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Gross Profit | $18.73 Million |
| Revenues | $58.55 Million |
| Income Tax Expense/Benefit, Deferred | $-1.52 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $-85.06 Million |
| Income/Loss From Continuing Operations After Tax | $-83.54 Million |
| Costs And Expenses | $147.62 Million |
| Net Income/Loss | $-83.54 Million |
| Basic Earnings Per Share | $0.28 |
| Income Tax Expense/Benefit | $-1.52 Million |
| Net Income/Loss Attributable To Parent | $-83.54 Million |
| Diluted Average Shares | $303269.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $-83.54 Million |
| Operating Expenses | $107.80 Million |
| Research and Development | $68.25 Million |
| Operating Income/Loss | $-89.07 Million |
| Benefits Costs and Expenses | $143.62 Million |
| Basic Average Shares | $303269.00 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Cost Of Revenue | $39.82 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Diluted Earnings Per Share | $0.28 |
| Other Operating Expenses | $39.55 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $112.52 Million |
| Assets | $991.12 Million |
| Inventory | $38.58 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Current Assets | $460.00 Million |
| Other Non-current Assets | $380.02 Million |
| Noncurrent Assets | $492.54 Million |
| Other Current Liabilities | $86.37 Million |
| Equity Attributable To Parent | $773.46 Million |
| Equity | $773.46 Million |
| Liabilities | $217.66 Million |
| Noncurrent Liabilities | $99.60 Million |
| Current Liabilities | $118.06 Million |
| Accounts Payable | $31.69 Million |
| Liabilities And Equity | $991.12 Million |
| Current Assets | $498.58 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.